<![CDATA[Ferring Pharmaceuticals 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=20841>Sat, 18 Apr 2026 19:46:49 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Ferring Pharmaceuticals and Gallup Announce Landmark Global Public Attitudes Study on Fertility and Family-Building]]>https://www.newswire.co.kr/newsRead.php?no=1032479Thu, 16 Apr 2026 14:19:29 +0900<![CDATA[For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025]]>https://www.newswire.co.kr/newsRead.php?no=1030035Wed, 11 Mar 2026 08:44:19 +0900<![CDATA[With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?]]>https://www.newswire.co.kr/newsRead.php?no=1023979Wed, 26 Nov 2025 16:20:00 +0900<![CDATA[Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®]]>https://www.newswire.co.kr/newsRead.php?no=1021739Thu, 30 Oct 2025 09:00:04 +0900<![CDATA[Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec]]>https://www.newswire.co.kr/newsRead.php?no=1018655Fri, 12 Sep 2025 15:20:00 +0900<![CDATA[Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta]]>https://www.newswire.co.kr/newsRead.php?no=1014243Wed, 02 Jul 2025 17:08:47 +0900<![CDATA[Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1]]>https://www.newswire.co.kr/newsRead.php?no=1009823Tue, 22 Apr 2025 10:20:00 +0900<![CDATA[Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin]]>https://www.newswire.co.kr/newsRead.php?no=1009105Wed, 09 Apr 2025 15:28:04 +0900<![CDATA[Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility]]>https://www.newswire.co.kr/newsRead.php?no=998020Fri, 04 Oct 2024 16:50:00 +0900<![CDATA[Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study]]>https://www.newswire.co.kr/newsRead.php?no=997824Wed, 02 Oct 2024 09:42:27 +0900<![CDATA[Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring]]>https://www.newswire.co.kr/newsRead.php?no=987538Tue, 09 Apr 2024 14:28:49 +0900<![CDATA[Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement]]>https://www.newswire.co.kr/newsRead.php?no=980727Mon, 11 Dec 2023 16:00:00 +0900<![CDATA[Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)]]>https://www.newswire.co.kr/newsRead.php?no=972898Thu, 24 Aug 2023 15:45:00 +0900<![CDATA[Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors]]>https://www.newswire.co.kr/newsRead.php?no=969265Thu, 22 Jun 2023 14:25:00 +0900<![CDATA[Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million]]>https://www.newswire.co.kr/newsRead.php?no=968932Fri, 16 Jun 2023 14:16:06 +0900<![CDATA[Four Analyses of Data for REBYOTA™ (fecal microbiota, live - jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023]]>https://www.newswire.co.kr/newsRead.php?no=966614Wed, 10 May 2023 10:15:00 +0900<![CDATA[최초로 FDA가 승인한 재발성 클로스트리듐 디피실 감염 예방 위한 마이크로비옴 기반 치료제 레비오타의 데이터 분석 4가지, 2023년 DDW서 발표]]>https://www.newswire.co.kr/newsRead.php?no=966615Wed, 10 May 2023 10:15:00 +0900<![CDATA[Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health]]>https://www.newswire.co.kr/newsRead.php?no=965350Tue, 18 Apr 2023 17:07:32 +0900<![CDATA[Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine]]>https://www.newswire.co.kr/newsRead.php?no=963170Wed, 15 Mar 2023 14:40:00 +0900<![CDATA[페링, 태평양 생식의학 협회 회의에서 Rekovelle®에 대한 최초의 전향적·다국적·실제 연구 초록 발표]]>https://www.newswire.co.kr/newsRead.php?no=963281Wed, 15 Mar 2023 14:40:00 +0900<![CDATA[Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) - A Novel First-in-Class Microbiota-Based Live Biotherapeutic]]>https://www.newswire.co.kr/newsRead.php?no=956989Fri, 02 Dec 2022 09:20:00 +0900<![CDATA[페링, 레비요타(REBYOTA®) 미국 FDA 승인 획득… 업계 최초의 미생물군 기반 생균 치료제]]>https://www.newswire.co.kr/newsRead.php?no=957007Fri, 02 Dec 2022 09:20:00 +0900<![CDATA[Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic]]>https://www.newswire.co.kr/newsRead.php?no=954166Tue, 25 Oct 2022 16:55:00 +0900<![CDATA[페링, ACG 2022서 연구용 미생물군 기반 생물 치료제 RBX2660 관련 7가지 새로운 분석 발표]]>https://www.newswire.co.kr/newsRead.php?no=954167Tue, 25 Oct 2022 16:55:00 +0900<![CDATA[Ferring Presents New Subgroup Analyses of Health-Related Quality of Life and Safety and Efficacy Data at IDWeek 2022 for RBX2660, Its Investigational Microbiota-based Live Biotherapeutic]]>https://www.newswire.co.kr/newsRead.php?no=953918Fri, 21 Oct 2022 11:00:00 +0900